Axogen, Inc. (AXGN) on Tuesday reported financial results for the first quarter ended March 31, 2026, reflecting 26.6% revenue growth. In addition, the firm raised its full-year 2026 revenue guidance.
Following the news, AXGN is surging 9.02%, at $42.94.
Axogen develops and commercialises technologies for peripheral nerve regeneration and repair.
For the first quarter of 2026, net loss expanded to $19.58 million, or $0.38 per share, compared to $3.83 million, or $0.08 per share, in the prior year.
Adjusted net income was $4.1 million or $0.07 per share, compared to an adjusted net loss of $0.9 million, or $0.02 per share a year ago.
Revenue increased 26.6% to $61.46 million from $48.56 million in the prior year.
As of March 31, 2026, the firm had cash and cash equivalents, restricted cash, and investments of $103.6 million.
Looking ahead, the firm raised its revenue guidance to at least 20%, or $270 million, for the full year, up from at least 18%, or $265.7 million, expected earlier.
"We are pleased with our first-quarter revenue performance and the progress we're making across each of Axogen's strategic plan priorities," said Michael Dale, President and CEO of Axogen.
AXGN has traded between $9.22 and $45.75 over the last year. AXGN closed Monday's trade at $39.39.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.